12:44 PM EST, 11/10/2025 (MT Newswires) -- (Updates with the latest stock price movement in the headline and the first paragraph.)

Cogent Biosciences ( COGT ) shares rose nearly 144% in recent Monday trading after it said that a phase 3 trial evaluating a combination of bezuclastinib and sunitinib in patients with imatinib-resistant or intolerant gastrointestinal stromal tumors, or GIST, showed higher progression-free survival and objective response rates compared with sunitinib monotherapy.

The biotech firm said the combination achieved a median progression-free survival of 16.5 months, compared with sunitinib monotherapy's progression-free survival of 9.2 months. The combination achieved a 46% objective response rate, compared with 26% for the sunitinib monotherapy, the company added.

Cogent said it expects to file a new drug application with the US Food and Drug Administration for bezuclastinib in GIST in H1 of 2026.

Price: 36.05, Change: +21.23, Percent Change: +143.25